Related Experiment Video
Updated: Aug 9, 2026
Strategies for Study of Neuroprotection from Cold-preconditioning
Published on: September 3, 2010
Discovery of molecular mechanisms of neuroprotection using cell-based bioassays and oligonucleotide arrays
Satinder S Sarang1, Takumi Yoshida, Rodolphe Cadet
1Biotechnology Center, Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Cambridge, Massachusetts 02139, USA.
Abstract:
Oxidative injury and the resulting death of neurons is a major pathological factor involved in numerous neurodegenerative diseases. However, the development of drugs that target this mechanism remains limited. The goal of this study was to test a compound library of approved Food and Drug Administration drugs against a hydrogen peroxide-induced oxidant injury model in neuroblastoma cells. We identified 26 neuroprotective compounds, of which megestrol, meclizine, verapamil, methazolamide, sulindac, and retinol were examined in greater detail. Using large-scale oligonucleotide microarray analysis, we identified genes modulated by these drugs that might underlie the cytoprotection. Five key genes were either uniformly upregulated or downregulated by all six drug treatments, namely, tissue inhibitor of matrix metalloproteinase (TIMP1), ret-proto-oncogene, clusterin, galanin, and growth associated protein (GAP43). Exogenous addition of the neuropeptide galanin alone conferred survival to oxidant-stressed cells, comparable to that seen with the drugs. Our approach, which we term "interventional profiling," represents a general and powerful strategy for identifying new bioactive agents for any biological process, as well as identifying key downstream genes and pathways that are involved.
Insights
Researchers screened FDA-approved drugs to find treatments for neurodegenerative diseases. They identified several neuroprotective compounds and key genes, including galanin, that protect neurons from oxidative injury.
Area of Science:
- Neuroscience
- Pharmacology
- Cell Biology
Background:
- Oxidative injury and neuronal death are key factors in neurodegenerative diseases.
- Developing effective drugs targeting these mechanisms remains a challenge.
Purpose of the Study:
- To screen Food and Drug Administration (FDA)-approved drugs for neuroprotective effects against oxidative stress.
- To identify genes and pathways involved in drug-induced cytoprotection.
Main Methods:
- Utilized a hydrogen peroxide-induced oxidant injury model in neuroblastoma cells.
- Screened a library of FDA-approved drugs.
- Performed large-scale oligonucleotide microarray analysis to identify modulated genes.
- Investigated the role of specific genes, including galanin, in cytoprotection.
Main Results:
- Identified 26 neuroprotective compounds, with six (megestrol, meclizine, verapamil, methazolamide, sulindac, retinol) studied further.
- Discovered five key genes (TIMP1, ret-proto-oncogene, clusterin, galanin, GAP43) uniformly modulated by the drug treatments.
- Demonstrated that exogenous galanin alone conferred significant survival to oxidant-stressed cells.
Conclusions:
- The study identified novel neuroprotective drug candidates and elucidated key molecular pathways involved in neuronal survival.
- The neuropeptide galanin plays a crucial role in protecting neurons against oxidative stress.
- The 'interventional profiling' approach is a versatile strategy for discovering bioactive agents and understanding underlying biological mechanisms.
More Related Videos
08:23Real-Time Impedance-based Cell Analyzer as a Tool to Delineate Molecular Pathways Involved in Neurotoxicity and Neuroprotection in a Neuronal Cell Line
Published on: August 9, 2014
10:00In Vivo Forward Genetic Screen to Identify Novel Neuroprotective Genes in Drosophila melanogaster
Published on: July 11, 2019